News
FLXN
--
0.00%
--
Raymond James Maintains Their Buy Rating on Flexion Therapeutics (FLXN)
SmarterAnalyst · 1d ago
Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery
The FDA signed off Flexion Therapeutics Inc's 
Benzinga · 2d ago
FDA Clears Flexion Therapeutics' Drug Candidate For Post-Operative Pain
MT Newswires · 2d ago
Flexion Therapeutics (FLXN) Receives a Buy from Northland Securities
Northland Securities analyst Carl Byrnes maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $35.00. The company's
SmarterAnalyst · 2d ago
DJ Flexion Therapeutics Says FDA Clears FX301 Investigational New Drug Application
Dow Jones · 2d ago
Flexion shares gain 4% on FDA clearance of FX301 in post-operative pain
The FDA has cleared Flexion Therapeutics' (FLXN) Investigational New Drug ((IND)) application for FX301, a locally administered NaV1.7 inhibitor known as funapide, formulated for extended-release in a thermosensitive hydrogel.Funapide has
Seekingalpha · 2d ago
BRIEF-Flexion Announces FDA Clearance Of Investigational NDA For FX301
reuters.com · 2d ago
Flexion Therapeutics Announces FDA Clearance Of Investigational New Drug Application For FX301 In Post-Operative Pain
FX301 combines NaV1.7 inhibitor (funapide) with a proprietary thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block FX301 may provide 3 to 5 days of non-opioid pain relief while
Benzinga · 2d ago
Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative Pain
-- FX301 combines NaV1.7 inhibitor (funapide) with a proprietary thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block
GlobeNewswire · 2d ago
Bioadhesive Microspheres Market Industry 2021 Global Market Research report covers a detailed study of the Market size, growth, and share, trends, consumption, segments, application and Forecast 2026.
Mar 01, 2021 (The Expresswire) -- The increasing advancement in drug delivery systems is likely to propel the growth of the bioadhesive microspheres market...
The Express Wire · 2d ago
Osteoarthritis Pain Drug Market New Innovations Trends, Research, Global Share and Growth Factor
Comserve · 02/23 13:24
Joint Pain Injections Market Analysis By Industry Size, Share, Revenue Growth, Development and Demand Forecast
Japan, Japan, Tue, 23 Feb 2021 07:20:12 / Comserve Inc. / -- Joint Pain Injections Market Report Contain Size Analysis, Competitive Landscape, Revenue...
Comserve · 02/23 12:21
Flexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 42 Annual Raymond James Institutional Investors Conference. The virtual fire...
GlobeNewswire · 02/22 21:30
Joint Pain Injections Market | Strategic Assessment By Top Players 2027 | ARC
pune, India, Thu, 18 Feb 2021 00:51:57 / Comserve Inc. / -- The global Joint Pain Injections market is expected to grow at noteworthy CAGR around 8 %...
Comserve · 02/19 14:18
Flexion To Test Higher Dose Of FX201 Gene Therapy In Early-Stage Osteoarthritis Study
Benzinga · 02/18 19:15
Flexion Therapeutics (FLXN) Gets a Buy Rating from H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $25.00. The company's
SmarterAnalyst · 02/18 14:55
BRIEF-Flexion Therapeutics To Advance Investigational Gene Therapy Fx201 Into High Dose Cohort Of Phase 1 Clinical Trial In Knee Osteoarthritis And Expand Low And Mid Dose Treatment Groups
reuters.com · 02/18 12:50
Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups
-- First-in-human single ascending dose trial advances to high dose cohort following positive Data Monitoring Committee review of mid dose safety data
GlobeNewswire · 02/18 12:31
Joint Pain Injections Market In-deep Analysis and Experts Review Report Outlook – 2025 | Anika Therapeutics, Inc., Bioventus., Ferring Pharmaceuticals Inc., Sanofi S.A., Pfizer Inc., Eli Lilly and Company
Feb 15, 2021 (Market Insight Reports) -- The Joint Pain Injections Market research report 2021 provides a basic overview of the industry including...
Market Insight Reports · 02/15 10:14
Bioadhesive Microspheres Market Emerging Technologies, Key Players Analysis, Development, and Industry Expansion Strategies 2026
Feb 15, 2021 (The Expresswire) -- The increasing advancement in drug delivery systems is likely to propel the growth of the bioadhesive microspheres market...
The Express Wire · 02/15 06:01
Webull provides a variety of real-time FLXN stock news. You can receive the latest news about Flexion through multiple platforms. This information may help you make smarter investment decisions.
About FLXN
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.